Format

Send to

Choose Destination
Endocrine. 2015 Aug;49(3):620-7. doi: 10.1007/s12020-014-0506-5. Epub 2015 Feb 4.

Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros.

Author information

1
Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy, maurizio.rossini@univr.it.

Abstract

In glucocorticoid-induced osteoporosis (GIO), both bone formation and resorption are altered, however, with a relative prevalence of resorption, consistent with the positive results that have been reported with bisphosphonate treatment. Many studies have investigated the effect of bisphosphonates (BPs), a widely used class of anti-resorptive drugs, showing a positive effect on bone mineral density and fracture risk. Also in case of postmenopausal osteoporosis, the safety and cost-effectiveness profile of BPs in GIO appears good. Currently, the use of BPs is recommended at the earliest by all major scientific societies in postmenopausal women and men ≥50 years at high risk of fracture receiving glucocorticoid therapy. BPs are the most commonly used anti-osteoporotic agents and they remain the current standard of care for GIO.

PMID:
25649760
DOI:
10.1007/s12020-014-0506-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center